Home  »  Trendy Stocks   »  Vascular Biogenics Ltd. (VBLT) stock gains in the ...

Vascular Biogenics Ltd. (VBLT) stock gains in the pre-market session. Why is it so?

Vascular Biogenics Ltd. (VBLT) stock declined by 7.29% at the last trading close whereas the VBLT stock rises in the pre-market by 1.12% as of this writing. VBL Therapeutics, formerly Vascular Biogenics, is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of first-in-class therapies for cancer and immune/inflammatory indications.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


VBL has created three platform technologies:

  • A gene-therapy-based technology for treating newly established blood vessels with a cancer focus,
  • An antibody-based platform focusing MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids,
  • A group of small molecules for immune-related indications.

What is happening?

Today, VBLT confirmed the completion of its underwritten public offering of 6,901,790 ordinary shares, as well as pre-funded options to buy 8,050,000 ordinary shares in an underwritten public offering, at a public price of $1.90 per ordinary share and $1.89 per pre-funded warrant, to some holders. The pre-funded warrants enable holders who are restricted from owning VBLT shares above a defined ownership level (such as 4.99 percent or 19.99 percent) to invest additional funds. In fact, pre-funded warrants are the same as common stock without voting rights. VBL Therapeutics sold all of the shares in the offering.


Before deducting underwriting incentives and commissions, as well as VBL Therapeutics’ sales costs, the Company received nearly $28.3 million in gross proceeds from the public offering. The net proceeds from the sale will be used by VBL Therapeutics for working capital and other general corporate purposes.

The offering’s bookrunning manager was Guggenheim Securities, LLC. Oppenheimer & Co. Inc. was also a joint bookrunner on the deal. Co-managers were Roth Capital Partners and JonesTrading Institutional Services LLC.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam